PHA Pharmagest Interactive SA

Equasens: Acquisition of a majority stake in DIGIPHARMACIE

Equasens: Acquisition of a majority stake in DIGIPHARMACIE

Villers-lès-Nancy, 2 January 2024 - 6:00 p.m. (CET)

PRESS RELEASE

Acquisition of a majority stake in DIGIPHARMACIE,

An expert in digital and invoice management solutions for pharmacies

  • With this acquisition, Equasens Group:
    • Strengthens its offering of solutions for healthcare professionals and consolidates its position as a leading European provider of digital healthcare solutions.
    • Addresses the growing demand for digital invoicing solutions following the introduction of new obligations in France.
    • Gives pharmacists more time to devote to their patients in a context characterised by increasing difficulties in recruitment in France and Europe.

, a leading healthcare software publisher (Euronext Paris™ - Compartment A - ISIN: FR 0012882389 - Ticker EQS) today announces its acquisition of a 70% majority stake in the start-up .

An innovative and profitable young company

Based in the Paris region and created in 2019, DIGIPHARMACIE is a pure player in digital invoicing solutions for pharmacies. As a provider of SaaS (Software as a Service) solutions for pharmacies, the DNA of this French start-up, led by Yonathan BLAJMAN, David CHALOM and Jonathan FITOUSSI, includes a significant technological component by enabling pharmacies to automatically collect, centralise and store supplier invoices and using artificial intelligence to digitise and structure data flows to the applications used by their external accountants. DIGIPHARMACIE's ready-to-deploy offering also addresses the needs of the pharmaceutical industry. As such, it already complies with the obligation requiring all invoices to be sent and received electronically by 1 September 2026.

With an installed base of already nearly 70% of French pharmacies (13,000 pharmacy customers), nearly 300 accounting firms, including major national groups, and an agreement with nearly 80% of pharmacy groups, DIGIPHARMACIE processes more than 1 million invoices each month on its platform.

Reflecting its achievements, in 2023 DIGIPHARMACIE was a recipient of the Prix de l'Innovation PharmagoraPlus (PharmagoraPlus Innovation Award).

"This acquisition of a majority stake in Digipharmacie provides yet another confirmation of the Equasens Group's commitment to supporting innovative start-ups,” commented Denis SUPPLISSON, Chief Executive Officer of Equasens. "DIGIPHARMACIE has been profitable since its creation in 2019 and has very quickly become the leader in its market. As a result of this acquisition, we are now able to offer pharmacists and their chartered accountants a complete and disruptive solution to meet their needs in the area of electronic invoicing."

"We are delighted to become a member of the Equasens Group, which will provide us with invaluable expertise and support our continued growth and development” stated Yonathan BLAJMAN, pharmacist and co-founder of DIGIPHARMACIE, adding that "As a result of this alliance, we are now able to offer our customers a more comprehensive and innovative range of services, and address the growing need for more of effective and efficient digital solutions in the healthcare ecosystem."

Electronic invoicing: an indispensable new development for healthcare professionals in France.

Equasens' acquisition of a majority stake in DIGIPHARMACIE represents an important turning point in the digital transformation of the healthcare sector. On this basis, the two companies are now able to offer a comprehensive solution that addresses the new requirement for all invoices to be received in electronic form by 1 September 2026.

  • Time savings and improved back office efficiency: the DIGIPHARMACIE solution simplifies and automates invoice management processes, as well handling electronic bills of exchange. By generating time-savings of approximately 10 hours per month (DIGIPHARMACIE data), healthcare professionals are able to focus their attention on be more strategic, added-value for the benefit of patients.
  • Reduce costs and improve carbon footprint: e-invoicing reduces printing, eliminates paper archiving and simplifies invoice processing.
  • Improved security: digitising invoices through DIGIPHARMACIE means that data is stored securely on highly secure online servers.
  • Improved data quality and traceability: the DIGIPHARMACIE solution makes it possible to monitor the status of invoices in real time and guarantee the quality of the data, facilitating their processing by the management software system used by healthcare professionals and their accountants.
  • A simplified user experience with a mobile app that allows pharmacists to :
    • integrate invoices through the photo function,
    • integrate expense reports,
    • offering a vault for storing important and/or sensitive documents.

Through this collaboration, the two companies will be able to extend the range of functions available to pharmacists to further simplify and secure their administrative workload. It will also make it possible to extend this approach to other healthcare professionals.

About

Founded more than 35 years ago, Equasens Group, which now has more than 1400 employees in Europe, is the leading publisher of software solutions for the healthcare industry in terms of the diversity of its business applications and market share.

Equasens Group’s specialised business applications facilitate the day-to-day work of healthcare professionals and their teams, working in private practice, collaborative medical structures or healthcare establishments. The Group also provides comprehensive support to healthcare professionals in the transformation of their profession by developing electronic equipment, digital solutions and healthcare robotics, as well as financing and training adapted to their specific needs.

And reflecting the spirit of its tagline "more technology for more humanity", the Group is a leading provider of interoperability solutions that improve coordination between healthcare professionals, their communications and data exchange resulting in better patient care and a more efficient healthcare system.

Listed on Euronext Paris™ - Compartment A

Indexes: MSCI GLOBAL SMALL CAP - GAÏA Index 2020 - CAC® SMALL and CAC® All-Tradable

Included in the Euronext Tech Leaders segment and the European Rising Tech label

Eligible for the Deferred Settlement Service (“Service à Réglement Différé” - SRD) and equity savings accounts invested in small and mid caps (PEA-PME).

ISIN: FR 0012882389 – Ticker Code: EQS

Get all the news about the Equasens Group and on

CONTACTS

Analyst and Investor Relations:

Chief Administrative and Financial Officer: Frédérique SCHMIDT

Tel.: +33 (0)3 83 15 90 67 -

Financial Press:

FIN’EXTENSO - Isabelle APRILE

Tel.: +33 (0)6 17 38 61 78 –

Attachment



EN
02/01/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pharmagest Interactive SA

 PRESS RELEASE

EQUASENS : Modalités de mise à disposition de l'URD 2023

EQUASENS : Modalités de mise à disposition de l'URD 2023 Villers-lès-Nancy, le 30 avril 2024 – 18 :45 (CET) COMMUNIQUE DE PRESSEPour diffusion immédiate Mise à disposition du Document d’Enregistrement Universel 2023 annonce que son Document d’Enregistrement Universel 2023 a été déposé auprès de l’Autorité des Marchés Financiers (AMF) en date du 29 avril 2024 sous le numéro n° D.24-0366. Ce document est disponible sur le site Internet de l’AMF, -france.org, ainsi que sur le site Internet d’Equasens, . Les documents suivants, diffusés au titre de l’article 222-3 du Règlement Général de ...

Arnaud Riverain
  • Arnaud Riverain

EQUASENS (EQS) - RN 2023 : 2025, changement de braquet / Achat - Obj. ...

Résultats en ligne avec nos attentes Marge Ebitda 30,4% (attendu 30,5%), marge opérationnelle courante 25,4% (25,3% attendu, marge nette 22,2% (20,8% attendu) Gearing en légère amélioration -29,7% vs -28,5% en 2022 (-38,5% attendu) Dividende proposé 1,25 € +9,2% Objectif 2025 : croissance à 2 chiffres

 PRESS RELEASE

Equasens: 2023 Annual Results

Equasens: 2023 Annual Results Villers-lès-Nancy, 29 March 2024 - 6:00 p.m. (CET) PRESS RELEASE 2023 Annual Results Annual results impacted by the overperformance at the end of 2022 and early 2023 driven by solutions introduced under the Ségur programme as well as an unfavourable economic climate Revenue: €219.7m, +2.6% Net Profit: €48.9m, +0.4% Net Profit attributable to Group shareholders: €47.0m, +1.4% The Current Operating Margin remains at a high level (25.4%)Dividend proposal for FY 2023: €1.25 per share (+9.2%) In €m202120222023Change2023/2022Revenue193.1214.1219.7+2.6%Current O...

 PRESS RELEASE

EQUASENS : Résultats Annuels 2023

EQUASENS : Résultats Annuels 2023 Villers-lès-Nancy, le 29 mars 2024 - 18h00 (CET) COMMUNIQUE DE PRESSE Résultats Annuels 2023 Résultats impactés par une surperformance fin 2022 et début 2023 liée au déploiement des versions SEGUR et une conjoncture défavorable Chiffre d’affaires : +2,6% à 219,7 M€ Résultat Net : +0,4% à 48,9 M€ Résultat Net Part du Groupe : +1,4% à 47,0 M€ Rentabilité ROC/CA maintenue à un niveau élevé (25,4%)Dividende proposé au titre de l’exercice 2023 : 1,25€ par action (+9,2%) En millions d'euros202120222023Variation2023/2022Chiffre d’Affaires193,1214,1219,7+ 2,6 ...

 PRESS RELEASE

EQUASENS : BILAN SEMESTRIEL S2-2023 DU CONTRAT DE LIQUIDITE

EQUASENS : BILAN SEMESTRIEL S2-2023 DU CONTRAT DE LIQUIDITE Villers-lès-Nancy, le 07 février 2024 - 18h30 (CET) COMMUNIQUE DE PRESSE BILAN SEMESTRIEL S2-2023 DU CONTRAT DE LIQUIDITECONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT Au titre du contrat de liquidité confié par la société à la Société de Bourse Gilbert Dupont, à la date du 29 décembre 2023, les moyens suivants figuraient au compte de liquidité : -        Nombre d’actions : 3 468-        Solde en espèces : 89 589,07 € Au cours du 2ème semestre 2023, il a été négocié un total de : ACHAT42 199 titres2 945 478,15 €2 408 t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch